MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context

Haematologica

Volumn 96, Issue 5, 2011, Pages 779-783

  Kleppe, Maria ^a,b   Mentens, Nicole ^a,b   Tousseyn, Thomas ^c   Wlodarska, Iwona ^b   Cools, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cell line; Interleukin; Leukemia; Mouse; Thymocyte

Indexed keywords

BCR ABL PROTEIN; INTERLEUKIN 7; JANUS KINASE 1; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ CD8+ T LYMPHOCYTE; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; JAK1 GENE; MOUSE; NONHUMAN; NOTCH1 GENE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FUSION PROTEINS, BCR-ABL; HEK293 CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-7; JANUS KINASE 1; KARYOTYPING; MICE; MICE, INBRED BALB C; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79955741414     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.035931     Document Type: Article

References (26)

1. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-71.
2. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6(5):347-59.
3. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205 (4):751-8.
4. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 115(14):2845-51.
5. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23 (8):1374-7.
6. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-10.
7. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(6): 530-5.
8. Porcu M, Gielen O, Cools J, De Keersmaecker K. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica. 2009;94(3):435-7.
9. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA. 1988;85(23):9312-6.
10. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189 (9):1399-412.
11. Loriaux MM, Levine RL, Tyner JW, FrohlingS, Scholl C, Stoffregen EP, et al. Highthroughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008;111(9):4788-96.
12. Lierman E, Van Miegroet H, Beullens E, Cools J. Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. Haematologica. 2009;94(10):1440-4.
13. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003;5:204-10.
14. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109-18.
15. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-12.
16. Weisberg E, Roesel J, Bold G, Furet P, Jiang J, Cools J, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008;112(13): 5161-70.
17. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105(12):4849-52.
18. Palomero T, Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S205-10.
19. Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol. 2001;73(3):271-7.
20. Park JH, Adoro S, Guinter T, Erman B, Alag AS, Catalfamo M, et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxiclineage T cells. Nat Immunol. 11(3):257-64.
21. Singer A, Adoro S, Park JH. Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 2008;8(10):788-801.
22. Asnafi V, Le Noir S, Lhermitte L, Gardin C, Legrand F, Vallantin X, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol. 2010;148(1): 178-9.
23. Raanani P, Trakhtenbrot L, Rechavi G, Rosenthal E, Avigdor A, Brok-Simoni F, et al. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematol. 2005;113(3):181-9.
24. Prebet T, Mozziconacci MJ, Sainty D, Arnoulet C, Lafage M, Dastugue N, et al. Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. Leuk Lymphoma. 2009;50(3):485-7.
25. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 2004;10(11):1187-9.
26. Li S. Src-family kinases in the development and therapy of Philadelphia chromosomepositive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49(1):19-26.